D.E. Shaw & Co
NMRA icon

D.E. Shaw & Co’s Neumora Therapeutics NMRA Stock Holding History

D.E. Shaw & Co’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30,748
Closed -$30.7K – 4593
2025
Q1 		$30.7K Buy
+30,748
New +$52.6K ﹤0.01% 4085

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

D.E. Shaw & Co's NMRA Position: Q2 2025 in Review

D.E. Shaw & Co sold out of Neumora Therapeutics (NMRA) in Q2 2025, closing a stake of 30,748 shares — an estimated $30.7K sold.

D.E. Shaw & Co first reported a position in NMRA in Q1 2025 and held it in 1 quarter. The position peaked at $30.7K in Q1 2025. 98 funds tracked by Wall St. Rank hold NMRA as of Q2 2025.

  • D.E. Shaw & Co reported no remaining Neumora Therapeutics position as of Q2 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 30,748 Neumora Therapeutics shares in Q2 2025, an estimated $30.7K.
  • D.E. Shaw & Co first reported a position in Neumora Therapeutics in Q1 2025 and held it in 1 quarter.
  • D.E. Shaw & Co's Neumora Therapeutics position peaked at $30.7K in Q1 2025.
  • 98 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.